Efficacy and Safety of Desmopressin Add-On Therapy for Men with Persistent Nocturia on α-Blocker Monotherapy for Lower Urinary Tract Symptoms: A Randomized, Double-Blind, Placebo Controlled Study

What Was Tested

The paper reports a study of Vasopressin and Desmopressin, published as a randomized controlled trial.

The primary end point was to assess changes in the mean number of nocturia episodes from baseline to the final assessment.

Who Took Part

The age groups tagged for this paper are adults and middle-aged adults, men only.

The study included men 40 to 65 years old with lower urinary tract symptoms and persistent nocturia despite α-blocker therapy for at least 8 weeks.

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

Because people in this Vasopressin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind Vasopressin study, the assignments were hidden from both participants and investigators until the end.

A placebo (an inactive look-alike) gave the Vasopressin group a baseline to be compared against.

Other secondary end points and adverse events were evaluated.

What Was Measured

Topics PubMed links to this paper include Adrenergic alpha-Antagonists, Antidiuretic Agents, Deamino Arginine Vasopressin, Nocturia, Polyuria and Quality of Life.

The authors tagged it with the keywords lower urinary tract symptoms and urinary bladder.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vasopressin and Desmopressin.

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2017 (The Journal of urology), a journal based in United States.

More context: the Vasopressin compound page and the Desmopressin compound page, all human trials.